DDW 2022 Conference Coverage


 

Early Experience of Ustekinumab for Treatment of Moderate-To-Severe Inflammatory Bowel Disease in Patients Post-Liver Transplant

11 views
July 8, 2022
Comments 0
Login to view comments. Click here to Login